Table 1.
Clinical and molecular characteristics of TRIBE2 CRCAssigner patients
| Characteristics No. (%) |
Enterocyte (N = 127) | Goblet-like (N = 55) | Inflammatory (N = 35) | Stem-like (N = 90) | Transit-amplifying (N = 69) | Mixed (N = 52) | P |
|---|---|---|---|---|---|---|---|
| Median age (range), years | 60 (34-75) | 60 (34-75) | 59 (43-70) | 60 (29-74) | 62 (39-75) | 63 (34-74) | 0.54 |
| Sex | 0.43 | ||||||
| Male | 77 (61) | 29 (53) | 16 (46) | 48 (53) | 44 (64) | 31 (60) | |
| Female | 50 (39) | 26 (47) | 19 (54) | 42 (47) | 25 (36) | 21 (40) | |
| ECOG PS | 0.01 | ||||||
| 0 | 104 (82) | 49 (89) | 30 (86) | 81 (90) | 69 (100) | 45 (87) | |
| 1-2 | 23 (18) | 6 (11) | 5 (14) | 9 (10) | 0 | 7 (13) | |
| Synchronous metastases | 0.004 | ||||||
| Yes | 114 (90) | 53 (96) | 32 (91) | 85 (94) | 53 (77) | 47 (90) | |
| No | 13 (10) | 2 (3) | 3 (9) | 5 (6) | 16 (23) | 5 (10) | |
| Prior adjuvant chemotherapy | 0.11 | ||||||
| Yes | 0 | 0 | 0 | 1 (1) | 3 (4) | 1 (2) | |
| No | 127 (100) | 55 (100) | 35 (100) | 89 (99) | 66 (96) | 51 (98) | |
| Primary tumor site | <0.001 | ||||||
| Right | 37 (29) | 34 (62) | 20 (57) | 40 (44) | 21 (30) | 28 (54) | |
| Left or rectum | 90 (71) | 21 (38) | 15 (43) | 50 (56) | 48 (70) | 24 (46) | |
| Liver only disease | 0.20 | ||||||
| Yes | 33 (26) | 11 (20) | 12 (34) | 30 (33) | 26 (38) | 12 (23) | |
| No | 94 (74) | 44 (80) | 23 (66) | 60 (67) | 43 (62) | 39 (75) | |
| Missing data | 0 | 0 | 0 | 0 | 0 | 1 (2) | |
| Resected primary tumor | <0.001 | ||||||
| Yes | 32 (25) | 28 (51) | 29 (83) | 85 (94) | 49 (71) | 40 (77) | |
| No | 95 (75) | 27 (49) | 6 (17) | 5 (6) | 20 (29) | 12 (23) | |
| Molecular status | <0.001 | ||||||
| RAS mutated | 85 (67) | 35 (63) | 20 (57) | 58 (64) | 40 (58) | 36 (69) | |
| BRAF mutated | 7 (5) | 12 (22) | 10 (29) | 6 (7) | 1 (1) | 9 (17) | |
| RAS and BRAF wild-type | 30 (24) | 6 (11) | 4 (11) | 24 (27) | 26 (38) | 6 (12) | |
| Missing data | 5 (4) | 2 (4) | 1 (3) | 2 (2) | 2 (3) | 1 (2) | |
| Microsatellite status | 0.005 | ||||||
| MSS/pMMR | 119 (94) | 53 (96) | 27 (77) | 87 (97) | 65 (94) | 47 (90) | |
| MSI-high/dMMR | 6 (5) | 2 (4) | 6 (17) | 1 (1) | 2 (3) | 2 (4) | |
| Missing data | 2 (1) | 0 | 2 (6) | 2 (2) | 2 (3) | 3 (6) | |
| Treatment arm | 0.70 | ||||||
| Doublet/bev | 64 (50) | 32 (58) | 16 (46) | 46 (51) | 34 (49) | 31 (60) | |
| Triplet/bev | 63 (50) | 23 (42) | 19 (54) | 44 (49) | 35 (51) | 21 (40) |
bev, bevacizumab; CRC, colorectal cancer; dMMR, deficient mismatch repair; ECOG PS, Eastern Cooperative Oncology Group performance status; MSI-high, high microsatellite instability; MSS, microsatellite stable; pMMR, proficient mismatch repair.
Statistically significant P values are reported in italics.